PO.IM01.15 · 免疫学
Monoclonal Antibodies and Antibody-Cytokine Platforms
-
- 4331 4331 ZL-1222，一种PD-1靶向的效力降低型IL-12免疫细胞因子，克服PD-1抗性并增强抗肿瘤免疫，且具有可接受的安全性特征 ZL-1222, a PD-1-targeted potency-reduced IL-12 immunocytokine, overcomes PD-1 resistance and enhances antitumor immunity with an accepted safety profile Cathy Wang, Lina Wang, Xue Wang, Xinchuan Dai, Qiuping Ye, Wilson Peng, Ziruo Wen, Lei Wang, Changwei Lv, Min Chen, Donghui Li, Qidong Hu, Bing Wan, Linda N. Liu
- 4332 4332 AR166，一种首创的PD-1×LAG-3×IL-2v三特异性免疫细胞因子，递送顺式作用IL-2v以克服免疫检查点抑制剂抗性 AR166, a first-in-class PD-1xLAG-3xIL-2v tri-specific immunocytokine delivering Cis -acting IL-2v to overcome immune checkpoint inhibitor resistance Jaeho Song, Seon-mi Yu, Jae-Seok Lee, Jinkeol Mok, WooJeong Lee, Seo-Young Koo, Ye Rim Gu, Min-Young Park, Seoyun Yang, Juhan Yoon, Young Woo Park, Wooick Jang, Su-Hyung Park
-
-
- 4335 4335 JMB2403：一种潜在同类最佳的 PD-1 依赖性 IL2Rβγ 靶向三特异性抗体，用于安全且强效的免疫治疗 JMB2403, a potential best-in-class PD-1-dependent IL2Rbetagamma-targeting tri-specific antibody for safe and potent immunotherapy Chunyin Gu, Deyi Wang, Yan Wang, Fangfang Jia, Fu Zhou, Shun Chang, Yu Zhao, Linlin Liu, Huawei Zhang, Peipei Liu, Xiaodan Cao, Taylor B. Guo
-
- 4337 4337 TGI-17b：一种潜在同类首创的 PD-1/VEGF/IL-2 α 偏向性三特异性抗体，泛癌治疗潜在的下一代基石 TGI-17b: A potential first-in-class PD-1/VEGF/IL-2 alpha-bias trispecific antibody and the potential next generation cornerstone for pan-cancer therapy Guoshuai Cao, Yangyang Li, Yuwei Wu, Haoyu Sun, Zhigang Tian
-
-
- 4340 4340 AZD6750：一种 CD8α 引导的 IL-2 免疫细胞因子，与 rilvegostomig（一种 PD-1/TIGIT 双特异性抗体）有效联用以增强内源性免疫 AZD6750, a CD8alpha-guided IL-2 immunocytokine effectively combines with rilvegostomig, a PD-1/TIGIT bispecific antibody, to enhance endogenous immunity Matthew J. Elder, Aidan H. Riley, Sin Lih Tan, Jerome Mastio, Bruno Frederico, Fabien Garcon, Hena Khalique, Georgina Bowyer, Paul Chariou, Nicholas M. Durham, Maria Broggi, Emily Hsiue, Simon Rodney, Jonathan B. Fitzgerald, Nadia Luheshi, Mark Cobbold, Saso Cemerski, Simon J. Dovedi
- 4341 4341 一种新型 αPD-1/αVEGF/IL-21v 三特异性融合蛋白表现出超越 αPD-1/αVEGF 双特异性疗法的强效抗肿瘤疗效 A novel alphaPD-1/alphaVEGF/IL-21v tri-specific fusion protein exhibits potent antitumor efficacy beyond alphaPD-1/alphaVEGF bispecific therapy Suna Kim, Sunjung Cho, Hyojoo Bang, So Woon Kim, Yongjun Jung, Seokchan Kang, Suyoon Kim, Mi-Seong Kim, Jun-Eui Park, Young Jin Park, Sungyoub Jung
-
- 4343 4343 一种新型抗PD-1/IL-15融合蛋白JMT108（SYS6090），具有高度选择性的PD-1⁺免疫细胞激活作用和强效抗肿瘤疗效 A novel anti-PD-1/IL-15 fusion protein JMT108 (SYS6090) with highly selective PD-1⁺ immune cell activation and potent anti-tumor efficacy Ke He, Yushan Kong, Jun Mu, Hongyan Wang, Yisha She, Yanfang Su, Yi Fan, Liping Song
-
-
-
-
- 4348 4348 一种人源化抗VEGFR-1单克隆抗体及其衍生的抗体-药物偶联物靶向肿瘤细胞和肿瘤微环境组分的抗癌活性 Anticancer activity of a humanized anti-VEGFR-1 monoclonal antibody and its derived antibody-drug conjugates targeting tumor cells and tumor-microenvironment components Pedro M. Lacal, Maria Grazia Atzori, Claudia Ceci, Federica Ruffini, Sonia Valentini, Lauretta Levati, Grazia Graziani
-
-
-
-
- 4353 4353 PHST001，一种人源化抗CD24 hIgG4抗体，对转移性肿瘤有效，并在竞争性IgG存在下保留其抗肿瘤活性 PHST001, a humanized anti-CD24 hIgG4 antibody, is effective against metastatic tumors and retains its anti-tumor activity in the presence of competing IgG Suzana A. Kahn, Joseane Sampaio, Douglas V. Faget, Rachel E. Brewer, Giovanni C. Forcina, Blacker Grace, Priyanka R. Malusare, Alexandria Beans, Seth D. Ludwig, John S. Burg, Jennifer Yinuo Cao, Raphaël F. Rousseau, Amira A. Barkal, Ravi Majeti, Irving L. Weissman, Roy L. Maute
-
- 4355 4355 基于冷冻电镜的IMC-002结构表征——一种具有独特结合位点和候选生物标志物的下一代抗CD47抗体，支持其增强安全性和疗效的证据 Cryo EM-based structural characterization of IMC-002, a next-generation anti-CD47 antibody with a unique binding site and biomarker candidates, supporting evidence of enhanced safety and efficacy Hyesun Lee, Jiyea Choi, HyeHyeon Jang, Heewook Shin, Jiyoung Yoon, Woochan Hwang, Sung Ho Kim, Heung Tae Kim
-
-
